YPrime has more than 10 years of experience designing cloud-based technological solutions to meet the needs of tomorrow’s clinical trials. Our eCOA and IRT solutions, clinical and data science expertise, patient insights, and clinical trial experience combine to improve the clinical trial experience for patients, sites, and sponsors. To learn more, visit https://www.yprime.com/

ABL, an Institut Mérieux Company, is a contract research and contract manufacturing organization offering full-service Immunology services to advance biologics from discovery to clinical phases. Established in 1961 as a biomedical research contractor for the government, ABL has contributed to the development of vaccines and therapeutics for major diseases and has developed a wide range of assays for various indications and treatments. To learn more, please visitwww.ablinc.com

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com.

AIQ’s TRAQinform IQ software quantifies and classifies lesion-specific treatment response and organ-specific toxicity from longitudinal imaging scans. It can deliver an early prediction of optimal/suboptimal responders to therapies allowing for optimal patient selection and more efficient go/no-go clinical decisions. It also provides concordance between multiple imaging modalities and radiotracers.

Axiom Healthcare Strategies is a boutique oncology think-tank, offering premier strategy and management consulting to biotechnology and pharmaceutical clients in the oncology and rare disease space. Our engagements focus exclusively on high-value contributions to our clients’ most critical challenges, and our depth of knowledge in oncology is unparalleled by any other firm. Learn more at www.axiomhcs.com.